Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
However, it is unclear whether this growth could cause cancer or exacerbate existing tumors
Patients who meet eligibility criteria can potentially access the medication before approval through trial participation
ATTAIN-2 (NCT05872620) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of various doses of orforglipron with placebo in adults with obesity or overweight and type 2 diabetes
S., Rose, L., Hansen, T., Zacho, J., & Pieber, T
These changes are generally attributed to the rate and magnitude of weight loss rather than a direct effect of the medication on reproductive tissues
US$ 24.22
US$ 23.46
US$ 21.74
US$ 24.98
US$ 20.94
US$ 25.56
US$ 23.21
US$ 20.95
US$ 21.30
